key: cord-0838677-e910jtx0 authors: Hosseinzadeh, Mohammad Hossein; Goodarzi, Amin; Malekan, Mohammad; Ebrahimzadeh, Mohammad Ali title: Melatonin increased hypoxia‐inducible factor (HIF) by inhibiting prolyl hydroxylase: A hypothesis for treating anaemia, ischaemia, and covid‐19 date: 2022-03-25 journal: Clin Exp Pharmacol Physiol DOI: 10.1111/1440-1681.13639 sha: 18c70bf25cc0c6fd2527d2e4fb4129c097f9a9c1 doc_id: 838677 cord_uid: e910jtx0 Hypoxia-Inducible Factor (HIF) is a transcriptional factor that acts as an oxygen sensor in the cells. It is constantly secreted in the cell and hydroxylated by prolyl hydroxylase (PH) under normal conditions. Melatonin is a neurohormone that is often secreted in the nervous system by the pineal gland. Melatonin increases vascular endothelial growth factor, anti-inflammatory agents, and inhibits reactive oxygen species (ROS). Melatonin is effective in treating anemia, ischemia and heart disease, inflammatory diseases, and covid-19. Melatonin may exert these effects by inhibiting PH and increasing HIF. This article is protected by copyright. All rights reserved. Melatonin is a neurohormone that is often secreted in the nervous system by the pineal gland. Melatonin is effective in treating anaemia, 7 ischaemia and heart disease, 8 testing. This appears to be associated with ACE2 receptor uptake or receptor depletion due to hormonal regulation. 14 The lower risk of infection and severity of the disease in children 15 and the higher resistance of bats to viral diseases (especially for COVID-19 infection), which had a higher melatonin level in the body, could confirm this hypothesis. Melatonin potentially helps decrease tissue inflammation by reducing TNF-α, IL-6, and IL-10. Indeed, PH inhibitors stabilised the DNA of lymphocytes and ultimately increased the immune system's resistance. 16 Two randomised, double-blind clinical trials showed that daily use of melatonin (3 mg/day) could significantly reduce cough rate, dyspnoea, fatigue, C-reactive protein levels, pulmonary involvement, time of hospitalisation, time of return to baseline health, 9 and improve blood oxygen saturation. 10 Also, a meta-analysis of three randomised controlled trials confirmed that MLT consumption increases clinical recovery rate, decreases risk of intensive care unit admission, and mortality rate in covid-19 patients. 17 However, further large-scale researches are needed to decisive conclusion. In contrast, Park et al. reported that melatonin did not affect the degradation of HIF-1α in prostate cancer cells. 18 Also, Li et al. showed that melatonin increases the expression of PH genes in atherosclerotic plaque. 19 But we know that the ROS level is elevated remarkably in cancerous and atherosclerotic cells due to the chronic and severely hypoxic conditions. 20, 21 The high level of ROS in cells inhibited PH through a cascade reactions activation. 6 So, PH inhibition activity of melatonin, HIF production, and biological pathway may be affected in these conditions. Most synthetic PH inhibitors (vadadustat, molidustat, roxadustat, etc.) are in various phases of trials and have not yet been definitively approved. Also, they showed important adverse effects with considerable prevalence rate. [22] [23] [24] Nowadays, MLT is known as a safe drug for long-term consumption compared to other sedative drugs. Many clinical trials evaluated its various effects and its safety. 25 If further studies confirm the PH inhibitory activity of MLT, it could be used as an available primary safe treatment. In addition, studies may lead to discovering new pharmacophores and compounds with fewer side effects. The available evidence for the effects of melatonin on the VEGF, ROS, ACE2, anti-inflammatory agents level and their effects on the improvement of ischaemia, anaemia, and COVID-19, which are all affected by HIF secretion, showed that melatonin may exert the mentioned effects by inhibiting the PH and increasing the HIF level (a new pharmacological mechanism for melatonin). So, more studies are needed. Pharmacologic targeting of hypoxia-inducible factors The role of hypoxiainducible factor-1alpha and its signaling in melanoma Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD HIF prolyl hydroxylase inhibitors for COVID-19 treatment: pros and cons HIF-α prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review Effects of melatonin on the body composition, physical performance, and blood erythrocyte indexes of C57Bl/6J mice exposed to continuous illumination Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, Double-blind Clinical Trial Melatonin effects on sleep quality and outcomes of COVID-19 patients: an open-label, randomized, controlled trial its beneficial effects on embryogenesis from mitigating oxidative stress to regulating gene expression The influence of melatonin and light on VEGF secretion in primary RPE cells Effect of melatonin versus injectable platelet rich fibrin on critical wound healing in submandibular salivary glands of diabetic rats Individualizing risk prediction for positive coronavirus disease 2019 testing: results from 11,672 patients Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections Possible prophylactic approach for SARS-CoV-2 infection by combination of melatonin, vitamin C and zinc in animals Efficacy of melatonin in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials Melatonin down-regulates HIF-1α expression through inhibition of protein translation in prostate cancer cells Melatonin enhances atherosclerotic plaque stability by inducing prolyl-4-hydroxylase α1 expression ROS and the DNA damage response in cancer Oxidative stress in atherosclerosis Safety and efficacy of vadadustat for anemia in patients undergoing dialysis Efficacy and safety of Molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study Clinical uses of melatonin: evaluation of human trials ACKNOWLEDGEMENTS None to declare. The authors declare no conflict of interest.